Edition:
United Kingdom

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

73.19USD
18 Apr 2019
Change (% chg)

$-0.73 (-0.99%)
Prev Close
$73.92
Open
$73.20
Day's High
$73.54
Day's Low
$72.23
Volume
6,764,507
Avg. Vol
3,921,194
52-wk High
$83.81
52-wk Low
$56.26

Select another date:

Tue, Mar 19 2019

U.S. FDA approves Roche's small cell lung cancer treatment

March 18 Swiss drugmaker Roche Holding AG's U.S. unit Genentech said on Monday its immunotherapy Tecentriq won approval for a tough-to-treat type of lung cancer, the latest win for the drug whose sales trail medicines from Merck & Co and Bristol-Myers Squibb.

French court dismisses damages claims against Merck over thyroid drug

LYON, France A court in the French city of Lyon threw out on Tuesday claims made by 4,113 plaintiffs for damages against Merck over changes to its thyroid drug Levothyrox.

French court dismisses damages claims against Merck over thyroid drug

LYON, France, March 5 A court in the French city of Lyon threw out on Tuesday claims made by 4,113 plaintiffs for damages against Merck over changes to its thyroid drug Levothyrox.

Versum unveils plan to fend off hostile takeover

United States based Versum Materials on Thursday unveiled a plan to prevent a hostile takeover in the face of an unsolicited $5.9 billion offer from Germany's Merck.

UPDATE 1-Versum unveils plan to fend off hostile takeover

* Versum plan designed to stop outsider from taking control (Recasts with details of Versum's plan, adds Merck comment)

AstraZeneca's Lynparza meets main goal in late-stage pancreatic cancer study

British drugmaker AstraZeneca Plc said on Tuesday its cancer drug being jointly developed with U.S.-based Merck & Co met the primary goal in a late-stage study for a rare type of pancreatic cancer.

AstraZeneca's Lynparza meets main goal in late-stage pancreatic cancer study

British drugmaker AstraZeneca Plc said on Tuesday its cancer drug being jointly developed with U.S.-based Merck & Co met the primary goal in a late-stage study for a rare type of pancreatic cancer.

UPDATE 1-AstraZeneca's Lynparza meets main goal in late-stage pancreatic cancer study

Feb 26 British drugmaker AstraZeneca Plc said on Tuesday its cancer drug being jointly developed with U.S.-based Merck & Co met the primary goal in a late-stage study for a rare type of pancreatic cancer.

Merck to buy immunotherapy developer Immune Design for $300 million

Merck & Co Inc said on Thursday it would buy drug developer Immune Design Corp for nearly $300 million, to gain access to its immunotherapy programs.

UPDATE 1-Merck to buy immunotherapy developer Immune Design for $300 mln

Feb 21 Merck & Co Inc said on Thursday it would buy drug developer Immune Design Corp for nearly $300 million, to gain access to its immunotherapy programs.

Select another date: